首页> 美国卫生研究院文献>Oncotarget >One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer
【2h】

One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer

机译:用于检测和治疗口腔鳞癌的单珠单化合物组合文库衍生的靶向配体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oral squamous cancers (OSC) are hallmarked by poor prognosis, delayed clinical detection, and a lack of defined, characteristic biomarkers. By screening combinatorial one-bead one-compound (OBOC) peptide libraries against oral squamous cancer cell lines, two cyclic peptide ligands, LLY12 and LLY13 were previously identified. These ligands are capable of specific binding to the oral cancer cell lines (MOK-101, HSC-3, SCC-4 and SCC-10a) but not non-cancerous keratinocytes, leukocytes, fibroblast, and endothelial cells. These two peptides were synthesized and evaluated for their binding property, cytotoxicity and cell permeability. In vitro studies indicate that both LLY12 and LLY13 were able to bind to oral cancer cells with high specificity but did not show any cytotoxicity against human keratinocytes. Biotinylated LLY13, in complex with streptavidin-alexa488 was taken up by live oral cancer cells, thus rendering it as an excellent candidate vehicle for efficient delivery of drug loaded-nanoparticles. In vivo and ex vivo near infra-red fluorescence imaging studies confirmed the in vivo targeting efficiency and specificity of LLY13 in oral cancer orthotopic murine xenograft model. In vivo studies also showed that LLY13 was able to accumulate in the OSC tumors and demarcate the tumor margins in orthotopic xenograft model. Together, our data supports LLY13 as a promising theranostic agent against OSC.
机译:口腔鳞癌(OSC)的标志是预后差,临床检测延迟和缺乏明确的特征性生物标志物。通过筛选针对口腔鳞状癌细胞系的组合单珠单化合物(OBOC)肽文库,先前鉴定了两个环状肽配体LLY12和LLY13。这些配体能够与口腔癌细胞系(MOK-101,HSC-3,SCC-4和SCC-10a)特异性结合,但不能与非癌性角质形成细胞,白细胞,成纤维细胞和内皮细胞特异性结合。合成这两种肽并评估其结合特性,细胞毒性和细胞通透性。体外研究表明,LLY12和LLY13都能够以高特异性结合口腔癌细胞,但对人角质形成细胞没有任何细胞毒性。与链霉亲和素-alexa488结合的生物素化LLY13被口腔癌细胞吸收,因此使其成为有效递送载有纳米颗粒的优秀候选载体。体内和离体近红外荧光成像研究证实了在口腔癌原位鼠异种移植模型中LLY13的体内靶向效率和特异性。体内研究还表明,LLY13能够在OSC肿瘤中积聚并在原位异种移植模型中划分肿瘤边缘。总之,我们的数据支持LLY13作为有希望的OSC治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号